Monitor ASCO presentation on May 30 for updated DOR/PFS data from silevertinib in frontline NSCLC; positive data could drive a significant upside. Current cash runway supports operations into 2H 2028, reducing near-term dilution risk.
Price Chart
Executive Summary
Black Diamond Therapeutics reported Q1 2026 EPS of -$0.16, beating consensus of -$0.21, with $0 revenue as expected. Net loss narrowed to $9.0M from $15.1M in Q4 2025, and cash runway extends into 2H 2028. The upcoming ASCO oral presentation of silevertinib Phase 2 data is a key near-term catalyst.
Key Financial Metrics
Key Facts
- Q1 2026 EPS: -$0.16 (beat consensus of -$0.21 by 23.8%)
- Revenue: $0 (in line with consensus)
- Net loss: $9.0M vs net income of $56.5M in Q1 2025 (due to prior-year license revenue)
- Cash, cash equivalents, and investments: $118.3M as of March 31, 2026
- Operating cash burn: $10.2M in Q1 2026
- First patient dosed in Phase 2 GBM trial; ASCO oral presentation (May 30) for NSCLC data
Financial Impact
EPS beat of $0.05 per share vs consensus, but no revenue impact
Risk Factors
- Clinical trial failure or disappointing ASCO data
- Dilution risk from future capital raises
- Competition from other EGFR inhibitors
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001701541-26-000015 |
| Document: bdtx-20260507.htm | 0001701541-26-000015 |
| Document: 0001701541-26-000015-index-headers.html | 0001701541-26-000015 |
| Document: 0001701541-26-000015-index.html | 0001701541-26-000015 |
| Document: 0001701541-26-000015.txt | 0001701541-26-000015 |
| 8-K Data (Synthetic) | 0001701541-26-000015 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 15, 2026 10w ago | Institutional Cluster | $2.05 $2.06 | ▲ +0.49% | ▲ +1.16% | $1.69 (−17.56%) |
Aug 5, 2026 11w ago | 8-K | $1.92 $1.95 | ▲ +1.56% | ▲ +0.95% | $1.69 (−11.98%) |
May 21, 2026 22w ago | 8-K | $2.28 $2.33 | ▲ +2.19% | ▲ +1.61% | $1.69 (−25.88%) |
May 21, 2026 22w ago | Press Release | $2.28 $2.33 | ▲ +2.19% | ▲ +1.61% | $1.69 (−25.88%) |
May 7, 2026 24w ago | 8-K | $2.72 $2.99 | ▲ +9.93% | ▲ +9.10% | $1.69 (−37.87%) |
Apr 21, 2026 26w ago | Press Release | $3.15 $3.35 | ▲ +6.35% | ▲ +5.33% | $1.69 (−46.35%) |
Mar 16, 2026 32w ago | Press Release | $2.23 $2.17 | ▼ −2.69% | ▼ −1.29% | $1.69 (−24.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers